5Babinow BE.Nanosuspensions in drug delivery[J].Nat Rev Drug Discov,2004,3(9):785-796.
6Rao GC,Kumar MS,Mathivanan N,et al.Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems[J].Pharmazie,2004,59(1):5-9.
9Jacobs C,Kayser O,Muller RH.Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide[J].Int J Pharm,2000,196(2):161-164.
10Muller RH,Peters K.Nanosnspensions for the formulation of poorly soluble drugs.1.Preparation by a size-reduction technique[J].Int J Pharm,1998,160(2):229-237.
5Moritera T, Ogura Y, Yoshimura N, et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy [ J ]. Invest Ophthalmol Vis Sci, 1992, 33( 11 ) :3125 - 3130.
6Gioedano G G, Refojo M F, Arroyo M H. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR [ J ]. Invest Ophthalmol Vis Sci, 1993,34 (9) :2743 - 2751.
7Araiz J J, Refojo M F, Arroyo M H, et al. Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy [ J ].Invest Ophthalmol Vis Sci, 1993,34(3 ) :522- 530.
8Lipinski C A.Drug-like properties and the causes of poor solubility and poor permeability[J].J Pharmacol Toxicol Methods,2000,44 (1):235-249.
9Na GC,Stevens HJ Jr,Yuan BO.et al.Physical stability of ethyl diatrizoate nanocrystalline suspension in steam sterilization[J].Pharm Res,1999,16 (4):569-574.
10Rabinow BE.Nanosuspensions in drug delivery[J].Nat Rev Drug Discov,2004,3 (9):785-796.
